natgillin/translations-raw huggingface dataset:
The set of floor panels according to claim 1, wherein the locking system is configured such that a vertical displacement of the second edge against the first edge during locking bends the strip downwards and turns the upper part of the locking element outwardly away from the upper edge. 
Komplet podnih ploča prema patentnim zahtjevima 1 ili 2, naznačen time,da je sustav za zaključavanje konfiguriran tako, da se zaključava putem vertikalnog premještavanja drugog kratkog brida prema prvom kratkom bridu.
A dose counter according to claim 1, wherein the chord defines a segment having at least 5%, of the area of the root circle. 
Brojač doze prema patentnom zahtjevu 2, pri čemu akord određuje segment koji ima najmanje 5%, poželjno najmanje 8%, još poželjnije najmanje 10% površine osnovnog kruga (134).
The dosage form according to the invention is thus suitable for preventing parenteral, nasal and/or oral abuse of pharmaceutical active ingredients with abuse potential. 
Oblik davanja prema izumu je stoga prikladan za sprečavanje parenteralne, nazalne i/ili oralne zlouporabe djelatnih tvari, prvenstveno farmaceutskih djelatnih tvari s potencijalom zlouporabe.
Use of a compound according to any one of Claims 1 to 3 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating a viral infection caused by a virus of the Flaviviridae family. 
Spoj iz bilo kojeg od patentnih zahtjeva od 1 do 19 za uporabu u inhibiranju HCV polimeraze ili za liječenje virusne infekcije uzrokovane virusom iz obitelji Flaviviridae.
An antigen binding protein of any one of claims 1-3, wherein said antibody fragment is a Fab fragment, a Fab' fragment, a F(ab')2 fragment, a Fv fragment, a diabody, or a single chain antibody molecule; 
Protein koji veže antigen u skladu s bilo kojim od patentnih zahtjeva 1-3, pri čemu navedeni fragment protutijela je Fab fragment, Fab' fragment, F(ab'), fragment, Fv fragment, dijatijelo, ili jednolančana molekula protutijela; navedeni protein koji veže antigen je ljudsko protutijelo; ili navedeni protein koji veže antigen je monoklonsko protutijelo.
In particularly preferred embodiments, all of the carboxylic acid groups in the third polymeric material are in the form of carboxylate anions. 
Polimer polikarboksilne kiseline koji je bar djelomično neutraliziran, pri čemu bar 90 % skupina karboksilne kiseline polimera polikarboksilne kiseline su u obliku anjona karboksilata.
(A1e) an amino group having a phenyl group having a halogen-substituted lower alkoxy group(s) as a substituent(s) on a phenyl group, and a lower alkyl group, or 
(Ale) amino skupinu koja ima fenilnu skupinu s halogen-supstituiranom skupinom (skupinama) niži alkil kao supstituentom (supstituentima) na fenilnoj skupini, te skupinu niži alkil, ili
The balloon catheter of claim 1, wherein the PEG fatty ester is selected from the group consisting of PEG glyceryl oleates, PEG glyceryl stearates, PEG sorbitan stearates, PEG sorbitan monolaurates, and PEG sorbitan monooleates. 
Medicinski uređaj prema zahtjevu 1, naznačen time, da je PEG-sorbitan ester masnih kiselina odabran od sljedećih: Tween"* 20, Tween* 40, Tween" 60 ili Tween" 80.
A double-stranded ribonucleic acid (dsRNA) for inhibiting expression of transthyretin (TTR), wherein said dsRNA comprises a sense strand and an antisense strand: 
Dvolančana ribonukleinska kiselina (dsRNA) za inhibiranje ekspresije transtiretina (TTR), naznačena time da
The devices prepared and used according to the present invention contain an opioid antagonist dispersed in microspheres. 
Uređaj za transdermalnu dostavu prema patentnom zahtjevu 4, naznačen time da je opioid antagonist raspršen u mikrosferama.
a hydroxypropyl methylcellulose in an amount of about 160 mg, wherein the hydroxypropyl methylcellulose has an apparent viscosity of 80,000 cP to 120,000 cP (nominal value 100,000 cP) when present in a 1% solution; 
(b) hidroksipropil metilcelulozu količinom od oko 160 mg, pri čemu hidroksipropil metilceluloza ima očit viskozitet od 80,000 cP do 120,000 cP (nominalna vrijednost 100,000 cP) kada je prisutna u 1%-tnoj otopini;
A pharmaceutical composition for use in the prevention or treatment of pain comprising: a first pharmacologically active ingredient selected from the compound according to chemical formula (I) and the physiologically acceptable salts thereof and 
Farmaceutski pripravak naznačen time da je za uporabu za sprječavanje 1li liječenje boli koji sadrži: a) prvi farmakološki aktivni sastojak izabran od spoja prema kemijskoj formuli (1) i njihove fiziološki prihvatljive soli
Viewed from one aspect the invention provides a pyrethroid or pyrethrin pediculicide for use in a method of treatment of a human subject to combat infestation by multicellular ectoparasites with exoskeletons, in particular head lice, which method comprises topically applying to said subject a first and a second pediculicide, said first pediculicide being a carbamate or organophosphate pediculicide and said second pediculicide being a pyrethroid or pyrethrin pediculicide, characterized in that said second pediculicide is applied between 15 minutes and 12 hours after the application of said first pediculicide. 
Piretroid ili piretrin za uporabu u postupku tretmana uzgajanih riba radi borbe protiv infestacije višestaničnim ektoparazitima sa egzoskeletom, taj postupak obuhvaća uzastopni topikalni tretman uzgajanih riba s prvim i drugim sredstvom protiv morskih uši, to prvo sredstvo protiv morskih uši je karbamat ili organofosfat i drugo sredstvo protiv morskih uši je piretroid ili piretrin, pri čemu izloženost prvom sredstvu protiv morskih uši traje 10 minuta do 12 sati prije izlaganja drugom sredstvu protiv morskih uši.
The composition of claim 10, wherein the medication for improving cognition and/or inhibiting neurodegneration is selected from the group consisting of donepezil hydrochloride, tacrine, rivastigmine, memantine, physostigmine, lithium salts, nicotine, arecoline, huperzine alpha, selegiline, riluzole, vitamine C, vitamine E, carotenoids, and Ginkgo Biloba extract. 
Pripravak za upotrebu prema zahtjevu 9, naznačen time da je lijek za poboljšanje kognitivnih sposobnosti odabran iz skupine koja se sastoji od selegilina, donepezil hidroklorida, takrina, rivastigmina, memantina, fizostigmina, litijeve soli, nikotina, arekolina, alfa huperzina, selegilina, riluzola, vitamina C, vitamina E, karotenoida i ekstrakta ginkgo bilobe.
A loudspeaker/microphone device (7). 
- uređaj zvučnik/mikrofon (7).
The composition of any of claims 1-13 further comprising a group A polysaccharide of formula wherein R is a terminal reducing L-rhamnose or D-GlcpNAc and n is a number from about 3 to about 30. 
B-D-GlepNAc (I) gdje je R terminalna reducirajuća I-ramnoza ili d-GlepN Ac, a n je broj od otprilike 3 do otprilike 30.
The composition of claim 8 wherein component (f) comprises one or more polymerized fatty acids. 
Kompozicija prema patentnom zahtjevu 8 naznačena time što komponenta (f) sadrži jednu ili više polimeriziranih masnih kiselina.
The antibody of claim 1, wherein the antibody is an antibody fragment selected from the group consisting of Fab, Fab′, F(ab′)2, a single-chain antibody (scFv), a dimerized V region (Diabody), a disulfide-stabilized V region (dsFv), and a peptide comprising CDR. 
Protutijelo u skladu s patentnim zahtjevom 1 ili 2, naznačeno time što je protutijelo fragment protutijela, kojeg se bira iz skupine koju čine Fab, Fab', F(ab'),, jednolančano protutijelo (scFv), dimerizirano V područje (dijatijelo), te disulfidno stabilizirano V područje (dsFv).
provided that the bacterial infection is other than a Mycobacterial infection. 
pod uvjetom da bakterijska infekcija nije mikobakterijska infekcija
The compound or the salt thereof according to claim 1, wherein R1 is a chlorine atom, a bromine atom, an optionally substituted C1-6 alkyl group, an optionally substituted C3-8 cycloalkyl group, an optionally substituted aryl group, an optionally substituted aryloxy group, an optionally substituted C1-6 alkylthio group or an optionally substituted heterocyclic group. 
Spoj ili njegova sol u skladu s patentnim zahtjevom 1, naznačen time, da je R1 atom klora, atom broma, po izboru supstituirana C1-6 alkilna skupina, po izboru supstituirana C3-8 cikloalkilna skupina, po izboru supstituirana arilna skupina, po izboru supstituirana ariloksi skupina, po izboru supstituirana C1-6 alkiltio skupina ili po izboru supstituirana heterociklička skupina.
In another embodiment, the pH of the composition is 4.5. 
Vodena formulacija u skladu s patentnim zahtjevom 9, naznačena time što je pH 4,5.
The magnetic drive (26) of claim 2, wherein the driving member is disposed coaxially with the electric motor (28) and wherein the driving member and the electric motor (28) share a common shaft (70). 
Magnetni pogon (26) iz zahtjeva 2, pri čemu je pogonski član smješten koaksijalno s električnim motorom (28) i pri čemu pogonski član 1 električni motor (28) dijele zajedničku osovinu (70).
The anti-OX40 antibody of claim 3, which comprises a VH chain having an amino acid sequence according to: (SEQ ID NO: 24) EVQLQESGPGLVKPSDTLSLTCAVSGYSIASGYYWNWIRQPPGKGLEWM 
Protutijelo protiv OX40 u skladu s patentnim zahtjevom 3, naznačeno time što sadrži VH lanac koji ima aminokiselinski slijed:
Use according to claim 26, wherein the alkaline earth carbonates comprise natural ground calcium carbonate (GCC) such as marble, chalk or limestone, synthetic calcium carbonate such as precipitated calcium carbonates (PCC) such as aragonitic PCC, vateritic PCC and/or calcitic PCC, especially prismatic, rhombohedral or scalenohedral PCC or surface modified calcium carbonates, and miscellaneous analogue fillers containing calcium carbonates such as dolomite or mixed carbonate based fillers; various matter such as talc or analogues; mica, clay titanium dioxide, bentonite, magnesite, satin white, sepiolite, huntite, diatomite, silicates; and mixtures thereof. 
Uporaba prema zahtjevu 25, naznačena time da zemno alkalijski karbonati sadrže prirodni kalcijev karbonat (GCC) kao što je mramor, kreda ili vapnenac, sintetski kalcijev karbonat kao što su istaloženi kalcijevi karbonati (PCC) kao što je aragonitni PCC, vateritni PCC i/ili kalcitni PCC, naročito prizmatski, romboedarski ili skalenoedarski PCC ili površinski izmijenjeni kalcijevi karbonati, te različita analogna punila koja sadrže kalcijeve karbonate kao što su dolomit ili pomiješana punila na bazi kalcijevog karbonata; različite tvari kao što je talk ili analozi; tinjac, glina, titanijev dioksid, bentonit, magnezit, saten bijelo, sepiolit, huntit, dijatomit, silikati; i njihove smjese.
A peptide as claimed in any preceding claim, formulated for parenteral administration. 
Peptid za koji se traži zaštita u patentnim zahtjevima 1 ili 2, formuliran za parenteralnu primjenu.
providing a sliding door system comprising: 
nabavljanje sustava kliznih vrata (700) koji obuhvaća:
Utility of Compounds of the Invention as Screening Agents 
Datum objave europske prijave patenta:
The pharmaceutical composition according to any of claims 1 to 7, further comprising at least one suitable adjuvant, selected from the group comprising 1018 ISS, aluminium salts, Amplivax, AS15, BCG, CP-870,893, CpG7909, CyaA, dSLIM, GM-CSF, IC30, IC31, Imiquimod, ImuFact IMP321, IS Patch, ISCOMATRIX, JuvImmune, LipoVac, MF59, monophosphoryl lipid A, Montanide IMS 1312, Montanide ISA 206, Montanide ISA 50V, Montanide ISA-51, OK-432, OM-174, OM-197-MP-EC, ONTAK, PepTel vector system, PLG microparticles, resiquimod, SRL172, Virosomes and other Virus-like particles, YF-17DBCG, Aquila's QS21 stimulon, Ribi's Detox. 
Farmaceutski sastav prema bilo kojem zahtjevu od 1 do 4, koji nadalje uključuje najmanje jedan prikladan adjuvans odabran iz skupine koja sadrži 1018 ISS, aluminijeve soli, Amplivax, AS15, BCG, CP-870,893, CpG7909, CyaA, dSLIM, GM-CSF, IC30, IC31, imikvimod, ImuFact IMP321, IS Patch, ISCOMATRIX, JuvImmune, LipoVac, MFS59, monofosforilni lipid A, Montanide IMS 1312, Montanide ISA 206, Montanide ISA 50V, Montanide ISA-51, OK-432, OM-174, OM-197-MP-EC, ONTAK, vektorski sustav PepTel, PLG mikro-čestice, resikvimod, SRL172, Virosomes 1 druge čestice slične virusima, YF-17DBCG, stimulon QS21 kompanije Aquila Biotech, Ribi's Detox.
when G1 is CH, G2 is CH, G3 is CH, R1 is a chlorine atom, a bromine atom, an iodine atom, a C1-4 alkyl group, a trifluoromethyl group, a dibutylamino group, a methoxy group or a substituted phenyloxy group, R2 is -COOH and R3 is a hydrogen atom, then R4 is a group as represented by general formulas (2-1) to (2-3): (wherein 
kada je G1 CH, G2 je CH, G3 je CH, R1 je atom klora, atom broma, atom joda, C1-4 alkilna skupina, trifluorometilna skupina, dibutilamino skupina, metoksi skupina ili supstituirana feniloksi skupina, R2 je -COOH i R3 je atom vodika, tada je R4 skupina kao što je predstavljeno općim formulama (2-1) do (2-3): (pri čemu
processing circuitry configured to compare said received reflected pulse of output ultrasonic vibrations with a previously detected pulse of output ultrasonic vibrations reflected from said distal surface of said wall and received at said proximal surface to detect changes in said surface of said wall, wherein said received reflected pulse of output ultrasonic vibrations and said previously detected pulse of output ultrasonic vibrations comprise vibrations reflected from said distal surface of said wall in response to different pulses of input ultrasonic vibrations; and 
sklop za obradu konfiguriran za usporedbu navedene primljene ultrazvučne vibracije s prethodno detektiranim impulsom izlaza ultrazvučnih vibracija koji je reflektiran od navedene distalne površine navedene stjenke i primljen na navedenoj proksimalnoj površini radi otkrivanja promjena u navedenoj površini navedene stjenke
is O and Y is connected to X1 via an w-amino aminocarbonyl cyclization spacer being part of Y; 
je O, a Y je povezan s X1 preko w-amino-aminokarbonilne ciklizacijske razmaknice koja je dio Y;
having a bulk density of at least 0.4 g/mL, and/or 
ima gustoću zbijenosti od barem 0,5 g/ml, ili
For zirconia in the metastable tetragonal or cubic crystalline phase, the particle size is preferably in the range of 50-2000 nm, though it is believed that a mean particle size in the range of 50-1000 nm provides the best balance between optical and structural properties. 
Za cirkonijev oksid u metastabilnoj tetragonskoj ili kubičnoj kristalnoj fazi, veličina čestica je preferirano u rasponu od 50-2000 nm, mada se vjeruje da srednja vrijednost veličina čestica u rasponu od 50-1000 nm omogućuje najbolji balans između optičkih i strukturnih svojstava. čestice cirkonijeva oksida su sposobne proći kroz martenzitsku transformaciju pod djelovanjem ultrazvuka.
The compound of any one of clauses 37-40, wherein R4 and R5 are H. The compound of clauses 37-40, wherein R4 and R5 taken together form a 4 or 5-membered heterocyclic ring selected from the group consisting of azetidine, pyrrolidine, pyrazolidine, isooxazolidine, imidazolidine, oxazolidine, thiazolidine, and isothiazolidine. 
(b) uzeti zajedno tvore 4 ili 5-člani heterociklični prsten odabran od skupine koja se sastoji od azetidina, pirolidina, pirizolidina, izooksoazolidina, imidazolidina, okazolidina, tiazolidina 1 izotiazolidina; ili (c) uzeti zajedno tvore heteroaromatski prsten odabran od skupine koja se sastoji od imidazola, pirazola, oksazola, izoksazola, tiazola, piridina, diazina, oksazina i tiazina.
The compound or salt of claim 7 for use wherein said JAK is JAK2. 
Spoj ili sol prema zahtjevu 42 naznačen time da navedeni JAK je JAK2.
is selected from the group consisting of hydrogen, halo, hydroxy, methyl, cyclopropyl, and cyclobutyl; 
R2 je odabran iz skupine koja sadrži vodik, halo, hidroksi, metil, ciklopropil i ciklobutil;
The method according to any one of claims 6 to 8, further comprising: in the uplink synchronous status, not resetting a timer based on the timing deviation information included in the random access response (S02), wherein the uplink status is maintained until the timer expires. 
Sustav radio komunikacije prema zahtjevu 9 ili 10, naznačen time da korak odbacivanja nadalje sadrži, u sinkronom statusu uzlazne veze, ne provođenje usklađivanja vremena uzlazne veze na osnovi informacije o odstupanju vremena sadržane u primljenom odgovoru slučajnog pristupa (S02).
A compound of formula (I) or a pharmaceutically acceptable salt thereof wherein R1 represents C1 to 2 alkyl, cyclopropyl, OCH3, SCH3 or OCF3; said alkyl or cyclopropyl group being optionally further substituted by one or more fluoro atoms; and R2 represents C1 to 3 alkyl. 
S % € O naznačen time, da R' predstavlja Cl do 2 alkil, ciklopropil, OCH,, SCH. ili OCF,; a navedena alkilna ili ciklopropilna skupina eventualno može biti dodatno supstituirana sa jednim ili više fluoro atoma; i R" predstavlja C1 do 3 alkil.
Process for manufacturing high solids suspensions of mineral materials 
POSTUPAK ZA DOBIVANJE SUSPENZIJA SA VISOKIM UDJELOM KRUTIH MINERALNIH MATERIJALA
In this case during the test—i.e. 
U takvom slučaju, za vrijeme testiranja, tj.
The process according to any one of the preceding claims, characterized in that the obtained composite polymer material is micronized to yield an average grain size of less than 4 mm, preferably less than 3 mm and most preferably less than 2 mm. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da se dobiveni kompozitni polimerni materijal mikronizira da se dobije prosječna veličina zrna od manje od 4 mm.
In addition, the compounds of the present invention are also useful as an active ingredient for the preparation of a medicament for preventive and/or therapeutic treatment of neurodegenerative diseases such as Parkinson's disease, tauopathies (e.g. frontotemporoparietal dementia, corticobasal degeneration, Pick's disease, progressive supranuclear palsy) and other dementia including vascular dementia; acute stroke and others traumatic injuries; cerebrovascular accidents (e.g. age related macular degeneration); brain and spinal cord trauma; peripheral neuropathies; retinopathies and glaucoma; and other diseases such as non-insulin dependent diabetes (such as diabetes type II) and obesity; manic depressive illness; schizophrenia; alopecia; cancers such as breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia and several virus-induced tumors. 
Uz to, spojevi prema ovom izumu također su korisni kao aktivni sastojak u pripravi lijeka za sprječavanje i/ili terapijsko liječenje neurodegenerativnih bolesti, poput Parkinsonove bolesti, taupatija (primjerice frontotemporoparijetalna demencija, HR P20070328 T3 kortikobazalna degeneracija, Pickova bolest, progresivna supranuklearna paraliza) i drugih demencija, uključujući vaskularnu demenciju; akutni inzult, te druge traumatske ozljede; cerebrovaskularne akcidente (primjerice makularna degeneracija uzrokovana starošću); povrede mozga i kralježnične moždine; periferne neuropatije; retinopatije 1 glaukom; i other bolesti, poput dijabetesa neovisnog o inzulinu (poput dijabetesa tip II) i pretilosti; manično-depresivne bolesti; shizofrenije; alopecije; raka, poput raka dojke, karcinoma velikih stanica pluća, raka štitnjače, leukemije T- ili B-stanica, te nekih tumora uzrokovanih virusima.
A process according to claim 1 further comprising the conversion of the Darunavir from Step a) to Darunavir alcohol solvate before dissolving of the Darunavir alcohol solvate in a solvent. 
Postupak prema zahtjevu 1 naznačen time da dalje obuhvaća pretvorbu Darunavira iz koraka a) u alkoholni solvat Darunavira [image] [image] [image] [image] prije otapanja alkoholnog solvata Darunavira u otapalu.
Treatment of compound 1-2 with mercury acetate followed by hydrochloric acid affords 2-alkyl-naphtha[2,3-b]furan-4,9-dione 1-3. 
Kombinacija iz patentnog zahtjeva 1, pri čemu je prvi agens 2-acetilnafto[2,3-b]furan-4,9-dion ili njegova farmaceutski prihvatljiva sol ili solvat.
US 2009-0149541 A1). A medicament comprising glatiramer acetate for use in treating a patient who is suffering from relapsing-remitting multiple sclerosis or who has experienced a first clinical episode and is at high risk of developing clinically definite multiple sclerosis, wherein the medicament is to be administered in a regimen of three subcutaneous injections of a 40mg dose of glatiramer acetate every seven days with at least one day between each subcutaneous injection. 
Glatiramer acetat u obliku farmaceutskog sastava za uporabu u liječenju čovjeka kao pacijenta koji pati od relapsirajućeg oblika multiple skleroze, naznačen time, da se daje u režimu od tri supkutane injekcije dozom od po 40 mg glatiramer acetata svakog tjedna s barem jednim danom između svake supkutane injekcije i u čemu farmaceutski sastav nadalje sadrži manitol i ima pH u području od 5,5 do 7,0.
Container according to claim 13, wherein the recesses (13) are located at the same height in each wall. 
Spremnik u skladu s patentnim zahtjevom 13, naznačen time što otvori (15) se nalaze na istoj visini na svakoj stijenci.
The method of embodiment 28 wherein the polypeptide is an antibody. The method of embodiment 29 wherein the antibody is a monoclonal antibody. 
Postupak prema patentnim zahtjevima od 1 do 27, naznačen time, da je protutijelo monoklonsko protutijelo.
A method of treating a tumor or cancer in a subject comprising administering to the subject a therapeutically effective amount of the compound according to claim 1 . 
Spoj koji se, sukladno patentnom zahtjevu 1, koristi kao metoda liječenja tumora/karcinoma kod pojedinca.
relaying mine-detection data to a controller of the vehicle. The method as claimed in claim 12 comprising electrically insulating the electro-discharge nozzle from a water pump by an electrically insulating coupling, the water pump pressurizing the water to create a high-speed waterjet through the exit orifice. 
Metoda prema zahtjevu 12, koja obuhvaća električnu izolaciju elektroerozijske mlaznice (2b) od vodene pumpe (33) putem spojke za električnu izolaciju, s tim da vodena pumpa (33) stavlja vodu pod tlak u svrhu stvaranja mlaza vode kroz izlazni otvor (2c).
The method according to claim 19, wherein the disease or disorder is selected from the group consisting of schizophrenia, delusion disorders, movement disorders, anxiety disorder, obsessive-compulsive disorder, and cognitive function disorder. 
Spoj za upotrebu prema zahtjevu 14, naznačen time što je bolest ili poremećaj izabran 1z skupina koja se sastoji od shizofrenije, halucinogenih poremećaja, poremećaja pokreta, tjeskobnih poremećaja, opsesivno-kompulsivnih poremećaja 1 poremećaja kognitivnih funkcija.
The compound according to any of claims 1 to 10 for use as a medicament wherein the compound is used as a medicament in combination with one or more neuroleptic agents, wherein the one or more neuroleptic agents is selected from the group consisting of sertindole, olanzapine, risperidone, quetiapine, aripiprazole, haloperidol, clozapine, ziprasidone and osanetant. 
Uporaba u skladu s bilo kojim od patentnih zahtjeva 19-20, nadalje obuhvaća tvar odabranu iz grupe koja sadrži sertindol, olanzapin, risperidon, kvetiapin, aripiprazol, haloperidol, klozapin, ziprasidon i osanetant. Uporaba u skladu s bilo kojim od patentnih zahtjeva 19-20, pri čemu je psihoza ili bolest koja uključuje psihotične simptome shizofrenija.
is selected from the group consisting of H, C1-C3 alkyl, C1-C3 alkoxy, fluoro, chloro, OCF3, and halo-C1-C2-alkyl, which contains 1 to 5 halogens; 
je odabran od grupe koja se sastoji od C1-C4 alkila, halo, i halo-C1-C2-alkila, koji sadrži 1 do 5 halogena, gdje je halo F ili Cl;
A ship or floating platform propulsion assembly (1), comprising 
PATENTNI ZAHTJEVI Sklop broda ili porivne plutajuće platforme (1), obuhvaća